Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Budde

Showing results (21-30 of 155) with videos related to

Pageof 16
Sort By:
Transplantation Proceedings|September 25, 2002
FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patientsT Boehler, M Schuetz, K Budde, et al.
Transplantation Proceedings|September 25, 2002
Relevance and meaning of prostate cancer in kidney transplantationB Schönberger, M Giessing, H Vogler, et al.
Transplantation Proceedings|June 21, 2007
Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studiesC Legendre, D Cohen, M Zeier, et al.
Der Urologe. Ausg. A|December 6, 2005
[Modern immunosuppression following renal transplantation. Standard or tailor made?]K Budde, M Giessing, L Liefeldt, et al.
Transplantation Proceedings|August 15, 2002
Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantationK Budde, S Smettan, L Fritsche, et al.
Transplantation Proceedings|December 21, 2010
Why rejections are not biopsy proven: frequency and reasonsF Fleiner, P Glander, L Fritsche, et al.
Transplantation Proceedings|December 26, 2001
Case-based reasoning algorithm for kidney transplant monitoringL Fritsche, A Schlaefer, K Budde, et al.
Transplantation Proceedings|December 5, 2017
Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus DiseaseF Halleck, D Khadzhynov, E Schrezenmeier, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 2, 1999
De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infectionJ Waiser, K Budde, B Rudolph, et al.
Transplantation Proceedings|September 20, 2017
Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic FactorsM Dürr, N Lachmann, B Zukunft, et al.
Pageof 16

Showing results (21-30 of 155) with videos related to

Sort By:
Pageof 16
Transplantation Proceedings|September 25, 2002
FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patientsT Boehler, M Schuetz, K Budde, et al.
Transplantation Proceedings|September 25, 2002
Relevance and meaning of prostate cancer in kidney transplantationB Schönberger, M Giessing, H Vogler, et al.
Transplantation Proceedings|June 21, 2007
Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studiesC Legendre, D Cohen, M Zeier, et al.
Der Urologe. Ausg. A|December 6, 2005
[Modern immunosuppression following renal transplantation. Standard or tailor made?]K Budde, M Giessing, L Liefeldt, et al.
Transplantation Proceedings|August 15, 2002
Five year outcome of tacrolimus rescue therapy in late rejection after renal transplantationK Budde, S Smettan, L Fritsche, et al.
Transplantation Proceedings|December 21, 2010
Why rejections are not biopsy proven: frequency and reasonsF Fleiner, P Glander, L Fritsche, et al.
Transplantation Proceedings|December 26, 2001
Case-based reasoning algorithm for kidney transplant monitoringL Fritsche, A Schlaefer, K Budde, et al.
Transplantation Proceedings|December 5, 2017
Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus DiseaseF Halleck, D Khadzhynov, E Schrezenmeier, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 2, 1999
De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infectionJ Waiser, K Budde, B Rudolph, et al.
Transplantation Proceedings|September 20, 2017
Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic FactorsM Dürr, N Lachmann, B Zukunft, et al.
Pageof 16